511 related articles for article (PubMed ID: 33942348)
21. Outcomes of bendamustine- or cyclophosphamide-based first-line chemotherapy in older patients with indolent B-cell lymphoma.
Olszewski AJ; Butera JN; Reagan JL; Castillo JJ
Am J Hematol; 2020 Apr; 95(4):354-361. PubMed ID: 31849108
[TBL] [Abstract][Full Text] [Related]
22. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.
Olszewski AJ; Castillo JJ
Cancer; 2013 Feb; 119(3):629-38. PubMed ID: 22893605
[TBL] [Abstract][Full Text] [Related]
23. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
24. Lenalidomide plus rituximab (R
Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
[TBL] [Abstract][Full Text] [Related]
25. Nodal monocytoid B-cell lymphoma (nodal marginal-zone B-cell lymphoma).
Nathwani BN; Drachenberg MR; Hernandez AM; Levine AM; Sheibani K
Semin Hematol; 1999 Apr; 36(2):128-38. PubMed ID: 10319381
[TBL] [Abstract][Full Text] [Related]
26. Similar effectiveness of R-CHOP-14 and -21 in diffuse large B-cell lymphoma-data from the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Mohm J; Rauh J; Harde J; Kaiser-Osterhues A; Jänicke M; Marschner N;
Eur J Haematol; 2019 Nov; 103(5):460-471. PubMed ID: 31314918
[TBL] [Abstract][Full Text] [Related]
27. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4.
Walewski J; Paszkiewicz-Kozik E; Michalski W; Rymkiewicz G; Szpila T; Butrym A; Giza A; Zaucha JM; Kalinka-Warzocha E; Wieczorkiewicz A; Zimowska-Curyło D; Knopińska-Posłuszny W; Tyczyńska A; Romejko-Jarosińska J; Dąbrowska-Iwanicka A; Gruszecka B; Jamrozek-Jedlińska M; Borawska A; Hołda W; Porowska A; Romanowicz A; Hellmann A; Stella-Hołowiecka B; Deptała A; Jurczak W
Br J Haematol; 2020 Mar; 188(6):898-906. PubMed ID: 31792945
[TBL] [Abstract][Full Text] [Related]
28. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles.
Arcaini L; Paulli M; Boveri E; Vallisa D; Bernuzzi P; Orlandi E; Incardona P; Brusamolino E; Passamonti F; Burcheri S; Schena C; Pascutto C; Cavanna L; Magrini U; Lazzarino M
Cancer; 2004 Jan; 100(1):107-15. PubMed ID: 14692030
[TBL] [Abstract][Full Text] [Related]
29. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E
Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740
[TBL] [Abstract][Full Text] [Related]
30. Trends in incidence, therapy and outcome of localized nodal and extranodal marginal zone lymphomas: declining incidence and inferior outcome for gastrointestinal sites.
Kuper-Hommel MJ; van de Schans SA; Vreugdenhil G; van Krieken JH; Coebergh JW
Leuk Lymphoma; 2013 Sep; 54(9):1891-7. PubMed ID: 23302044
[TBL] [Abstract][Full Text] [Related]
31. Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.
Joshi M; Sheikh H; Abbi K; Long S; Sharma K; Tulchinsky M; Epner E
Ther Adv Hematol; 2012 Oct; 3(5):275-90. PubMed ID: 23616915
[TBL] [Abstract][Full Text] [Related]
32. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Zucca E; Conconi A; Pedrinis E; Cortelazzo S; Motta T; Gospodarowicz MK; Patterson BJ; Ferreri AJ; Ponzoni M; Devizzi L; Giardini R; Pinotti G; Capella C; Zinzani PL; Pileri S; López-Guillermo A; Campo E; Ambrosetti A; Baldini L; Cavalli F;
Blood; 2003 Apr; 101(7):2489-95. PubMed ID: 12456507
[TBL] [Abstract][Full Text] [Related]
33. Rituximab plus bendamustine is active in pretreated patients with extragastric marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Kiesewetter B; Mayerhoefer ME; Lukas J; Zielinski CC; Müllauer L; Raderer M
Ann Hematol; 2014 Feb; 93(2):249-53. PubMed ID: 23925930
[TBL] [Abstract][Full Text] [Related]
34. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
35. Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
Ueda K; Terui Y; Yokoyama M; Sakajiri S; Nishimura N; Tsuyama N; Takeuchi K; Hatake K
Leuk Lymphoma; 2013 Sep; 54(9):1928-33. PubMed ID: 23216271
[TBL] [Abstract][Full Text] [Related]
36. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Alderuccio JP; Arcaini L; Watkins MP; Beaven AW; Shouse G; Epperla N; Spina M; Stefanovic A; Sandoval-Sus J; Torka P; Alpert AB; Olszewski AJ; Kim SH; Hess B; Gaballa S; Ayyappan S; Castillo JJ; Argnani L; Voorhees TJ; Saba R; Chowdhury SM; Vargas F; Reis IM; Kwon D; Alexander JS; Zhao W; Edwards D; Martin P; Cencini E; Kamdar M; Link BK; Logothetis CN; Herrera AF; Friedberg JW; Kahl BS; Luminari S; Zinzani PL; Lossos IS
Blood Adv; 2022 Apr; 6(7):2035-2044. PubMed ID: 35196377
[TBL] [Abstract][Full Text] [Related]
37. Rituximab-Bendamustine (R-Benda) in MALT lymphoma complicating primary Sjögren syndrome (pSS).
Demaria L; Henry J; Seror R; Frenzel L; Hermine O; Mariette X; Nocturne G
Br J Haematol; 2019 Feb; 184(3):472-475. PubMed ID: 29424433
[No Abstract] [Full Text] [Related]
38. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease.
Oh SY; Kwon HC; Kim WS; Hwang IG; Park YH; Kim K; Ko YH; Ryoo BY; Kang HJ; Nam E; Lee JH; Kim JH; Kim HJ
Eur J Haematol; 2007 Oct; 79(4):287-91. PubMed ID: 17692101
[TBL] [Abstract][Full Text] [Related]
39. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study.
Fisher RI; Dahlberg S; Nathwani BN; Banks PM; Miller TP; Grogan TM
Blood; 1995 Feb; 85(4):1075-82. PubMed ID: 7849295
[TBL] [Abstract][Full Text] [Related]
40. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
